Morgan Stanley Crispr Therapeutics Ag Transaction History

Morgan Stanley

$1.49 Trillion
Q2 2025

A detailed history of Morgan Stanley transactions in Crispr Therapeutics Ag stock. As of the latest transaction made, Morgan Stanley holds 511,380 shares of CRSP stock, worth $28.9 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

511,380

Previous 1,299,982 60.66%

Holding current value

$28.9 Million

Previous $44.2 Million 43.77%

% of portfolio

0.0%

Previous 0.0%

24 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 15, 2025	SELL	$31.27 - $48.64 $24.7 Million - $38.4 Million	-788,602 Reduced 60.66%	511,380 $24.9 Million
Q1 2025 May 15, 2025	BUY	$34.03 - $53.02 $27.4 Million - $42.7 Million	804,980 Added 162.62%	1,299,982 $44.2 Million
Q4 2024 Feb 14, 2025	SELL	$38.65 - $55.15 $5.3 Million - $7.56 Million	-137,001 Reduced 21.68%	495,002 $19.5 Million
Q3 2024 May 14, 2025	BUY	$44.62 - $62.75 $1.53 Million - $2.15 Million	34,324 Added 5.74%	632,003 $29.7 Million
Q3 2024 Nov 14, 2024	BUY	$44.62 - $62.75 $1.53 Million - $2.15 Million	34,324 Added 5.74%	632,003 $29.7 Million
Q2 2024 May 14, 2025	BUY	$51.17 - $68.18 $5.25 Million - $7 Million	102,677 Added 20.74%	597,679 $32.3 Million
Q2 2024 Oct 17, 2024	SELL	$51.17 - $68.18 $25 Million - $33.3 Million	-488,245 Reduced 44.96%	597,679 $32.3 Million
Q2 2024 Aug 14, 2024	SELL	$51.17 - $68.18 $25 Million - $33.3 Million	-488,245 Reduced 44.96%	597,679 $32.3 Million
Q1 2024 Oct 17, 2024	BUY	$60.67 - $89.12 $29.6 Million - $43.5 Million	488,245 Added 81.69%	1,085,924 $74 Million
Q1 2024 Aug 16, 2024	BUY	$60.67 - $89.12 $40.8 Million - $60 Million	672,847 Added 162.89%	1,085,924 $74 Million
Q1 2024 May 15, 2024	BUY	$60.67 - $89.12 $40.8 Million - $60 Million	672,847 Added 162.89%	1,085,924 $74 Million
Q4 2023 Aug 16, 2024	SELL	$38.62 - $72.18 $7.13 Million - $13.3 Million	-184,602 Reduced 30.89%	413,077 $25.9 Million
Q4 2023 Feb 13, 2024	BUY	$38.62 - $72.18 $2.38 Million - $4.45 Million	61,642 Added 17.54%	413,077 $25.9 Million
Q3 2023 Nov 15, 2023	SELL	$45.39 - $59.0 $1.79 Million - $2.32 Million	-39,405 Reduced 10.08%	351,435 $16 Million
Q2 2023 Aug 14, 2023	SELL	$43.47 - $67.77 $3.46 Million - $5.4 Million	-79,686 Reduced 16.94%	390,840 $21.9 Million
Q1 2023 May 15, 2023	SELL	$41.0 - $56.12 $1.53 Million - $2.09 Million	-37,267 Reduced 7.34%	470,526 $21.3 Million
Q4 2022 Feb 14, 2023	SELL	$39.19 - $65.67 $3.06 Million - $5.13 Million	-78,051 Reduced 13.32%	507,793 $20.6 Million
Q3 2022 Nov 14, 2022	BUY	$61.1 - $83.78 $1.12 Million - $1.54 Million	18,386 Added 3.24%	585,844 $38.3 Million
Q2 2022 Oct 27, 2022	BUY	$43.23 - $73.83 $2.16 Million - $3.7 Million	50,070 Added 9.68%	567,458 $34.5 Million
Q2 2022 Aug 15, 2022	BUY	$43.23 - $73.83 $2.16 Million - $3.7 Million	50,070 Added 9.68%	567,458 $34.5 Million
Q1 2022 Oct 27, 2022	SELL	$53.19 - $79.24 $2.66 Million - $3.97 Million	-50,070 Reduced 8.82%	517,388 $32.5 Million
Q1 2022 May 13, 2022	SELL	$53.19 - $79.24 $1.39 Million - $2.07 Million	-26,122 Reduced 4.81%	517,388 $32.5 Million
Q4 2021 Feb 14, 2022	SELL	$70.09 - $111.29 $2.56 Million - $4.06 Million	-36,511 Reduced 6.29%	543,510 $41.2 Million
Q3 2021 Nov 15, 2021	BUY	$110.2 - $156.64 $63.9 Million - $90.9 Million	580,021 New	580,021 $64.9 Million

Others Institutions Holding CRSP

# of Institutions

529

Shares Held

68.7M

Call Options Held

3.67M

Put Options Held

2.25M

View Full List

About CRISPR Therapeutics AG

Ticker CRSP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 78,009,296
Market Cap $4.42B
Description
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA....

More about CRSP

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

News

Stay updated on Morgan Stanley with notifications on news.

Account